Large Dimeric Ligands with Favorable Pharmacokinetic Properties and Peroxisome Proliferator-Activated Receptor Agonist Activity in Vitro and in Vivo

Journal of Medicinal Chemistry

Volumn 46, Issue 23, 2003, Pages 4883-4894

  Sauerberg, Per ^a   Bury, Paul S ^a   Mogensen, John P ^a   Deussen, Heinz Josef ^a   Pettersson, Ingrid ^a   Fleckner, Jan ^a   Nehlin, Jan ^a   Frederiksen, Klaus S ^a   Albrektsen, Tatjana ^a   Din, Nanni ^a   Svensson, L Anders ^a   Ynddal, Lars ^a   Wulff, Erik M ^a   Jeppesen, Lone ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

Psa@novonordisk.com

Indexed keywords

2 ETHOXY 3 [4 (5 PHENYLPENT 2 EN 4 YNYLOXY)PHENYL]PROPIONIC ACID; 3 [4 (3 BIPHENYL 4 YLBUT 2 ENYLOXY)PHENYL] 2 ETHOXYPROPANOIC ACID; 3 [4 [3 [4' [4 [4 (ETHOXY 2 CARBOXYETHYL)PHENOXY]BUT 2 EN 2 YL]BIPHENYL 4 YL]BUT 2 EN 1 YLOXY]PHENYL] 2 ETHOXYPROPANOIC ACID; 3 [4 [5 [3 [5 [4 (2 CARBOXY 2 ETHOXYETHYL)PHENOXY]PENT 3 EN 1 YNYL]PENT 2 EN 4 YNYLOXY]PHENYL] 2 ETHOXYPROPANOIC ACID; 3 [4 [5 [4 [5 [4 (2 CARBOXY 2 ETHOXYETHYL)PHENOXY]PENT 3 EN 1 YNYL]PHENYL]PENT 2 EN 4 YNYLOXY]PHENYL] 2 ETHOXYPROPANOIC ACID; CARBACYCLIN; CLOFIBRATE; DIMER; FENOFIBRIC ACID; FURYLFURAMIDE; IMIDAZOLE; LIGAND; NNC 610029; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIOGLITAZONE; PIRINIXIC ACID; RECEPTOR SUBTYPE; ROSIGLITAZONE; UNCLASSIFIED DRUG; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; EXPERIMENTAL MODEL; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; MALE; MOUSE STRAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY;

EID: 0242299587     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0309046     Document Type: Article

References (43)

1. Porte, D., Jr.; Schwartz, M. W. Diabetes complications: Why is Glucose Potentially Toxic? Science 1996, 27, 699-700.
2. Chilcott, J.; Tappenden, P.; Jones, M. L.; Wright, J. P. A systematic Review of the Clinical Effictiveness of Pioglitazone in the treatment of type 2 Diabetes Mellitus. Clin. Ther. 2001, 23, 1792-1823.
3. Boyle, P. J.; King, A. B.; Olansky, L.; Marchetti, A.; Lau, H.; Magar, R.; Martin, J. Effects of Pioglitazone and Rosiglitazone on the Blood Lipid Levels and Glycemic Control in Patients with Type 2 Diabetes Melitus: A Retrospective Review of Randomly Selected Medical Records. Clin. Ther. 2002, 24, 3, 378-396.
4. Staels, B.; Dallongeville, J.; Auwerx, J.; Schoonjans, K.; Leitersdorf, E.; Fruchart, J.-C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998, 98, 2088-2093.
5. Oliver, W. R.; Shenk, J. L.; Snaith, M. R.; Russell, C. S.; Plunket, K. D.; Bodkin, N. L.; Lewis, M. C.; Winegar, D. A.; Sznaidman, M. L.; Lambert, M. H.; Xu, H. E.; Sternbach, D. D.; Kliever, S. A.; Hansen, B. C.; Willson, T. M. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 5306-5311.
6. Kliewer, S. A.; Umesono, K.; Noonan, D. J.; Heyman, R. A.; Evans, R. M. Convergence of 9-cis retinoic acid and peroxisome proliferator signaling pathways through heterodimer formation of their receptors. Nature 1992, 358, 771-774.
7. Strand, J.; Sandeman, D.; Skovsted, B.; Edsberg, B. Müller, P. Ragaglitazar (NNC 61-0029, (-) DRF 2725): The efficacy and Safety of the Novel Dual PPARα and PPARγ Agonist in Patients with Type 2 Diabetes. Diabetes 2002, 51, suppl. 2, A144.
8. Cronet, P.; Petersen, J. F. W.; Folmer, R.; Blomberg, N.; Sjöblom, K.; Karlsson, U.; Lindstedt, E.-L.; Bamberg, K.; Structure of the PPARα and -γ ligand binding domain in complex with AZ 242; Ligand selectivity and Agonist Activation in the PPAR family. Structure 2001, 9, 699-706.
9. Etgen, G. J.; Oldham, B. A.; Johnson, W. T.; Broderick, C. L.; Montrose, C. R.; Brozinick, J. T.; Misener, E. A.; Bean, J. S.; Bensch, W. R.; Brooks, D. A.; Shuker, A. J.; Rito, C. A.; McCarthy, J. R.; Ardecky, R. A.; Tyhonas, J. S. ; Dana, S. L.; Bilakovics, J. M.; Paterniti, J. R., Jr.; Ogilvie, K. M.; Liu, S.; Kauffman, R. F. A Tailored Therapy for the Metabolic Syndrome, The Dual Peroxisome Proliferator-Activated Receptor-α/γ Agonist LY465608 Ameliorates Insulin Resistance and Diabetes Hyperglycemia While Improving Cardiovascular Risk Factors in Preclinical Models. Diabetes 2002, 51, 1083-1087.
10. Lewis, M. C.; Winegar, D. A.; Bodkin, N. L.; Hansen, B. C.; Oliver, W. R. Improved Insulin Sensitivity and Dyslipidemia Following Oral Administration of Combination PPARγ/α and PPARδ Agonist in Obese Rhesus Monkeys. Diabetes 2002, 51, suppl. 2, A140.
11. Lewis, M. C.; Wilson, J. G.; Franklin, M. C.; Brown, J. G.; Strole, C. A.; Oliver, W. R.; Winegar, D. A. Co-Administration of PPARγ, α and δ Agonist, improves Efficacy Relative to PPARγ Agonist Alone in ZDF rats. Diabetes 2002, 51, suppl. 2, A140.
12. Mogensen, J. P.; Jeppesen, L.; Bury, P. S.; Pettersson, I.; Fleckner, J. ; Nehlin, J.; Frederiksen, K. S.; Albrektsen, T.; Din, N.; Mortensen, S. B.; Svensson, L. A.; Wassermann, K.; Wulff, E. M.; Ynddal, L.;Sauerberg, P. Design and synthesis of novel PPAR α/γ/δ triple activators using a known PPARα/γ dual activator as structural template. Bioorg. Med. Chem. Lett. 2003, 13, 257-260.
13. Sauerberg, P.; Pettersson, I.; Jeppesen, L.; Bury, P. S.; Mogensen, J. P.; Wassermann, K.; Brand, C. L.; Sturis, J.; Wöldike, H. F.; Fleckner, J. ; Andersen, A.-S. T.; Mortensen, S. B.; Svensson, L. A.; Rasmussen, H. B.; Lehmann, S. V.; Polivka, Z.; Sindelar, K.; Panajotova, V.; Ynddal, L.; Wulff, E. M. Novel tricyclic-α-alkoxyphenylpropionic Acids: Dual PPARα/γ Agonists with Hypolipidemic and Antidiabetic Activity. J. Med. Chem. 2002, 45, 789-804.
14. Ebdrup, S.; Pettersson, I.; Rasmussen, H. B.; Deussen, H.-J.; Jensen, A. F.; Mortensen, S. B.; Fleckner, J.; Pridal, L.; Nygaard, L.; Sauerberg, P. Synthesis, and Biological and Structural Characterization of the Dual Acting PPARα/γ Agonist Ragaglitazar. J. Med. Chem. 2003, 46, 1306-1317.
15. Allen, C. F. H.; Edens, C. O., Jr. Phenylpropargylaldehyde. Organic Syntheses; Wiley: New York, 1955; Collect. Vol. III, pp 731-733.
16. Krause, N. Synthesis of Allenes by 1,6-Addition of Organocuprates to Polarized Enynes. Chem. Ber. 1990, 123, 2173-2180.
17. Takeuchi, R.; Tanabe, K.; Tanaka, S. Stereodivergent Synthesis of (E)- and (Z)-2-Alken-4-yn-1-ols from 2-Propynoic Acid: A Practical Route via 2-Alken-4-ynoates. J. Org. Chem. 2000, 65, 1558-1561.
18. Taylor, E. C. Iminium Salts in Organic Chemistry. In Advances in Organic Chemistry: Methods and Results, Ed.; John Wiley & Sons: New York. 1979.
19. Willson, T. M.; Cobb, J. E.; Cowan, D. J.; Wiethe, R. W.; Correa, I. D.; Prakash, S. R.; Beck, K. D.; Moore, L. B.; Kliever, S. A.; Lehmann, J. M. The Structure-Activity Relationship between Peroxisome Proliferator-Activated Receptor y Agonism and the Antihyperglycemic Activity of Thiazolidinediones. J. Med. Chem. 1996, 39, 665-668.
20. Halazy, S. G-protein coupled receptor bivalent ligands and drug design. Exp. Opin. Ther. Pat. 1999, 9, 431-446.
21. Christopoulos, A.; Grant, M. K. O.; Ayoubzadeh, N.; Kim, O. N.; Sauerberg, P.; Jeppesen, L.; El-Fakahany, E. E. Synthesis and Pharmacological Evaluation of Dimeric Muscarinic Acetylcholine Receptor Agonists. J. Pharmacol. Exp. Ther. 2001, 298, 1260-1268.
22. Nolte, R. T.; Wisely, G. B.; Westin, S.; Cobb, J. E.; Lambert, M. H.; Kurokawa, R.; Rosenfeld, M. G.; Willson, T. M.; Glass, C. K.; and Milburn, M. V. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 1998, 395, 137-143.
23. Uppenberg, J.; Svensson, C.; Jaki, M.; Bertilsson, G.; Jendeberg, L.; Berkenstam, A. Crystal Structure of the Ligand Binding Domain of the Human Nuclear Receptor PPARγ. J. Biol. Chem. 1998, 273, 31108-31112.
24. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25.
25. Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular Properties That Influence the Oral Bioavailably of Drug candidates. J. Med. Chem. 2002, 45, 2615-2623.
26. Faber, K. N.; Müller, M.; Jansen, P. L. M. Drug transport proteins in the liver. Adv. Drug Delivery Rev. 2003, 55, 107-124.
27. Gampe, R. T.; Montana, V. G.; Lambert, M. H.; Miller, A. B.; Bledsoe, R. K.; Milburn, M. V.; Kliever, S. A.; Willson, T. M.; Xu, H. E. Asymmetry in the PARγ/RXRα Crystal Structure Reveals the Molecular Basis of Heterodimerization among Nuclear Receptors. Mol. Cell 2000, 5, 545-555.
28. Oberfield, J. L.; Collins, J. L.; Holmes, C. P.; Goreham, D. M.; Cooper, J. P.; Cobb, J. E.; Lenhard, J. M.; Hull-Ryde, E. A.; Mohr, C. P.; Blanchard, S. G.; Parks, D. J.; Moore, L. B.; Lehmann, J. M.; Plunket, K.; Miller, A. B.; Milburn, M. V.; Kliewer, S. A.; Willson, T. M. A peroxisome proliferator-activated receptor y ligand inhibits adipocyte differentiation. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 6102-6106.
29. Several other dimeric ligands have subsequently shown potent PPAR activity. Sauerberg et al. Unpublished.
30. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A Fast Docking Method using an Incremental Construction Algorithm J. Mol. Biol. 1996, 261, 470-489.
31. Kramer, B.; Rarey, M.; Lengauer, L. Evaluation of the FlexX incremental construction algorithm for protein-ligand docking. Proteins: Struct. Funct. Genet. 1999, 37, 228-241.
32. Rarey, M.; Wefing, S.; Lengauer, T. Placement of medium-sized molecular fragments into active sites of proteins. J. Comput.-Aided Mol. Design 1996, 10, 41-54.
33. Rarey, M.; Kramer, B.; Lengauer, T. Multiple automatic base selection: Protein-ligand docking based on incremental construction without manual intervention. J. Comput.-Aided Mol. Des. 1997, 11, 369-384.
34. Sotriffer, C. A.; Gohlke, H.; Klebe, G. Docking into Knowledge-Based Potential Fields: A Comparative Evaluation of Drug Score. J. Med. Chem. 2002, 45, 1967-1970.
35. Clark, R. D.; Strizhev, A.; Leonard, J. M.; Blake, J. F.; Matthew, J. B. Concensus scoring for ligand/protein interactions. J. Mol. Graph. Mod. 2002, 20, 281-295.
36. SYBYL 6.8 Tripos Inc., 1699 South Hanley Rd., St. Louis, MO 63144.
37. Cerenius, Y.; Ståhl, K.; Svensson, L. A.; Ursby, T.; Oskarsson, Å.; Albertsson, J.; Liljas, A. The crystallography beamline I711 at MAX II. J. Synchrotron Rat. 2000, 7, 203-208.
38. Kabsch, W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J. Appl. Crystallogr. 1993, 26, 795-800.
39. Brünger, A. T.; Krukowski, A.; Erickson, J. W. Slow-cooling protocols for crystallographic refinement by simulated annealing. Acta Crystallogr. Sect. A 1990, 46, 585-593.
40. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. Sect, D 1997, 53, 240-255.
41. Bailey. S. The ccp4 suite - programs for protein crystallography. Acta Crystallogr. Sect. D 1994, 50, 760-763.
42. Oldfield, T. J.; Hubbard, R. E. Analysis of c-alpha geometry in protein structures. Proteins 1994, 18, 324-337.
43. Kleywegt, G. J.; Jones, T. A. Databases in protein Crystallography. Acta Crystallogr. Sect. D 1998, 54, 1119-1131.